Literature DB >> 18433694

The cholesterol paradox revisited: heart failure, systemic inflammation, and beyond.

Stephan von Haehling1, Joerg C Schefold, Jochen Springer, Stefan D Anker.   

Abstract

The pathophysiologic understanding of chronic heart failure has made significant advances over the last decades. Counterintuitively, high levels of plasma cholesterol are associated with better survival, perhaps because plasma lipoproteins are able to scavenge lipopolysaccharide, a cell-wall component from gram-negative bacteria. A number of similar features are present in patients who have sepsis. This article explores the cholesterol paradox in patients who have chronic heart failure and extends this view to patients who have sepsis. Also discussed is the potential of statins, which might be able to exert beneficial effects in both clinical conditions, despite lowering plasma cholesterol values.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18433694     DOI: 10.1016/j.hfc.2008.01.009

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  4 in total

1.  ApoB-containing lipoproteins promote infectivity of chlamydial species in human hepatoma cell line.

Authors:  Yuriy K Bashmakov; Nailia A Zigangirova; Alexander L Gintzburg; Petr A Bortsov; Ivan M Petyaev
Journal:  World J Hepatol       Date:  2010-02-27

Review 2.  Statin treatment for patients with heart failure.

Authors:  W H Wilson Tang; Gary S Francis
Journal:  Nat Rev Cardiol       Date:  2010-03-16       Impact factor: 32.419

3.  Single baseline serum creatinine measurements predict mortality in critically ill patients hospitalized for acute heart failure.

Authors:  Joerg C Schefold; Mitja Lainscak; Lea Majc Hodoscek; Stefan Blöchlinger; Wolfram Doehner; Stephan von Haehling
Journal:  ESC Heart Fail       Date:  2015-09-21

4.  Leukocyte redistribution: effects of beta blockers in patients with chronic heart failure.

Authors:  Stephan von Haehling; Joerg C Schefold; Ewa Jankowska; Wolfram Doehner; Jochen Springer; Kristin Strohschein; Sabine Genth-Zotz; Hans-Dieter Volk; Philip Poole-Wilson; Stefan D Anker
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.